Bone Biologics Stock (BBLG) Skyrockets 100% Today—Here’s Why

Bone Biologics (BBLG) just pulled off a moonshot—shares doubled in a single trading session. No slow-and-steady here.

What’s fueling the frenzy?

Speculation’s running wild, but the market’s betting big on their next-gen bone graft tech. No FDA approval yet, but hey—since when did biotech traders wait for paperwork?

Short squeeze? Pump-and-dump? Retail FOMO? Take your pick. Wall Street’s playing pin-the-tail-on-the-catalyst while Main Street piles in.

One thing’s certain: someone’s getting rich, and it’s probably not you. Classic biotech casino—place your bets before the music stops.

Confident Investing Starts Here:

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Bone Biologics said the patent application WOULD strengthen its intellectual property portfolio and support its strategic plan to advance its clinical development program. The company is currently working with partners to build on preclinical data for the NELL-1 protein. This protein is in development to act as a bone graft substitute for spinal fusion procedures.

Jeffrey Frelick, CEO of Bone Biologics, said, “This patent application marks a major milestone in our mission to bring effective treatments to spine fusion patients.”

Bone Biologics Stock Movement Today

Bone Biologics stock was up 99.76% in pre-market trading on Friday. That’s a welcome change for a stock that is down 26.24% year-to-date and 43.17% over the past 12 months. The shares also saw heavy trading today, with over 15 million exchanged, compared to a three-month daily average of about 63,000 units.